Investment Thesis
Nu-Med Plus is in severe financial distress with negative stockholders' equity of -$215.1K, indicating the company is technically insolvent. Revenue has collapsed 400% YoY to negative territory while operating losses continue to mount, demonstrating fundamental business failure. The company has minimal cash reserves of $2.4K against $224.5K in liabilities and negative operating cash flow, indicating imminent insolvency without significant capital infusion.
Strengths
- Minimal capital expenditure requirements reduce cash burn in operations
- Zero long-term debt structure limits refinancing risk
- Severely distressed valuation may offer distressed asset recovery opportunity for turnaround specialists
Risks
- Negative stockholders' equity indicates technical insolvency and heightened bankruptcy risk
- Revenue collapse of 400% YoY demonstrates total loss of business viability
- Critical liquidity crisis with current ratio of 0.04x and only $2.4K cash against $224.5K liabilities
- Negative operating cash flow of -$4.4K indicates operational losses are not self-sustaining
- Complete absence of profitability with net income loss of $68.3K in latest period
- No insider buying activity in past 90 days suggests management confidence is absent
Key Metrics to Watch
- Stockholders equity trend - any improvement from negative -$215.1K position
- Monthly revenue stabilization - current negative revenue is unsustainable
- Cash burn rate and runway until complete depletion of $2.4K reserves
- Debt covenant compliance and default risk
- Asset liquidation values and going concern assessment
Financial Metrics
Revenue
-5.0K
Net Income
-68.3K
EPS (Diluted)
$0.00
Free Cash Flow
-4.4K
Total Assets
9.4K
Cash
2.4K
Profitability Ratios
Gross Margin
N/A
Operating Margin
1,266.6%
Net Margin
1,366.9%
ROE
N/A
ROA
-729.2%
FCF Margin
88.7%
Balance Sheet & Liquidity
Current Ratio
0.04x
Quick Ratio
0.04x
Debt/Equity
N/A
Debt/Assets
2,394.8%
Interest Coverage
-50.79x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-03T22:28:13.170545 |
Data as of: 2024-12-31 |
Powered by Claude AI